Is this the end for immunochemotherapy in relapsed/refractory chronic lymphocytic leukemia?

被引：2

作者：

Robak, Tadeusz ^{[1
,2
]}

机构：

[1] Med Univ Lodz, Copernicus Mem Hosp, Dept Hematol, Lodz, Poland

[2] Med Univ Lodz, Dept Hematol, Ciolkowskiego 2, PL-93510 Lodz, Poland

来源：

LEUKEMIA & LYMPHOMA | 2023年 / 64卷 / 05期

关键词：

RITUXIMAB; CYCLOPHOSPHAMIDE; BENDAMUSTINE; FLUDARABINE;

D O I：

10.1080/10428194.2023.2188103

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：907 / 909

页数：3

共 15 条

[1] Obinutuzumab plus bendamustine for relapsed/refractory chronic lymphocytic leukemia and predictive and prognostic impact of genetic alterations: the phase II GABRIELL study [J].

Bravo, Julio ;

Tello, Patricia Baltasar ;

Garcia, Esther Gonzalez ;

Herranz, Eduardo Rios ;

Payer, Angel Ramirez ;

Castera, Maria Jose Terol ;

Champ, Diana ;

Perez, Angeles Medina ;

Gironella, Mercedes ;

Zarzoso, Miguel Fernandez ;

Fores, Rafael ;

Delgado, Julio ;

Garcia-Marco, Jose A. ;

GABRIELL Study Group Investigators .

LEUKEMIA & LYMPHOMA, 2023, 64 (05) :913-926

[2] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia [J].

Byrd, J. C. ;

Brown, J. R. ;

O'Brien, S. ;

Barrientos, J. C. ;

Kay, N. E. ;

Reddy, N. M. ;

Coutre, S. ;

Tam, C. S. ;

Mulligan, S. P. ;

Jaeger, U. ;

Devereux, S. ;

Barr, P. M. ;

Furman, R. R. ;

Kipps, T. J. ;

Cymbalista, F. ;

Pocock, C. ;

Thornton, P. ;

Caligaris-Cappio, F. ;

Robak, T. ;

Delgado, J. ;

Schuster, S. J. ;

Montillo, M. ;

Schuh, A. ;

de Vos, S. ;

Gill, D. ;

Bloor, A. ;

Dearden, C. ;

Moreno, C. ;

Jones, J. J. ;

Chu, A. D. ;

Fardis, M. ;

McGreivy, J. ;

Clow, F. ;

James, D. F. ;

Hillmen, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) :213-223

[3] Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study [J].

Cuneo, Antonio ;

Follows, George ;

Rigolin, Gian Matteo ;

Piciocchi, Alfonso ;

Tedeschi, Alessandra ;

Trentin, Livio ;

Medina Perez, Angeles ;

Coscia, Marta ;

Laurenti, Luca ;

Musuraca, Gerardo ;

Farina, Lucia ;

Rivas Delgado, Alfredo ;

Orlandi, Ester Maria ;

Galieni, Piero ;

Mauro, Francesca Romana ;

Visco, Carlo ;

Amendola, Angela ;

Billio, Atto ;

Marasca, Roberto ;

Chiarenza, Annalisa ;

Meneghini, Vittorio ;

Ilariucci, Fiorella ;

Marchetti, Monia ;

Molica, Stefano ;

Re, Francesca ;

Gaidano, Gianluca ;

Gonzalez, Marcos ;

Forconi, Francesco ;

Ciolli, Stefania ;

Cortelezzi, Agostino ;

Montillo, Marco ;

Smolej, Lukas ;

Schuh, Anna ;

Eyre, Toby A. ;

Kennedy, Ben ;

Bowles, Kris M. ;

Vignetti, Marco ;

de la Seam, Javier ;

Moreno, Carol ;

Foa, Robin ;

Ghia, Paolo .

HAEMATOLOGICA, 2018, 103 (07) :1209-1217

[4]

Dyer, EHA LIB, pS151

[5] Chronic lymohocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Eichhorst, B. ;

Robak, T. ;

Montserrat, E. ;

Ghia, P. ;

Niemann, C. U. ;

Kater, A. P. ;

Gregor, M. ;

Cymbalista, F. ;

Buske, C. ;

Hillmen, P. ;

Hallek, M. ;

Mey, U. .

ANNALS OF ONCOLOGY, 2021, 32 (01) :23-33

[6] First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial [J].

Eichhorst, Barbara ;

Fink, Anna-Maria ;

Bahlo, Jasmin ;

Busch, Raymonde ;

Kovacs, Gabor ;

Maurer, Christian ;

Lange, Elisabeth ;

Koeppler, Hubert ;

Kiehl, Michael ;

Soekler, Martin ;

Schlag, Rudolf ;

Vehling-Kaiser, Ursula ;

Koechling, Georg ;

Ploeger, Christoph ;

Gregor, Michael ;

Plesner, Torben ;

Trneny, Marek ;

Fischer, Kirsten ;

Doehner, Harmut ;

Kneba, Michael ;

Wendtner, Clemens-Martin ;

Klapper, Wolfram ;

Kreuzer, Karl-Anton ;

Stilgenbauer, Stephan ;

Boettcher, Sebastian ;

Hallek, Michael .

LANCET ONCOLOGY, 2016, 17 (07) :928-942

[7] Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group [J].

Fischer, Kirsten ;

Cramer, Paula ;

Busch, Raymonde ;

Stilgenbauer, Stephan ;

Bahlo, Jasmin ;

Schweighofer, Carmen D. ;

Boettcher, Sebastian ;

Staib, Peter ;

Kiehl, Michael ;

Eckart, Michael J. ;

Kranz, Gabriele ;

Goede, Valentin ;

Elter, Thomas ;

Buehler, Andreas ;

Winkler, Dirk ;

Kneba, Michael ;

Doehner, Hartmut ;

Eichhorst, Barbara F. ;

Hallek, Michael ;

Wendtner, Clemens-Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (26) :3559-3566

[8] Acalabrutinib Versus Investigator's Choice in Relapsed/Refractory Chronic Lymphocytic Leukemia: Final ASCEND Trial Results [J].

Ghia, Paolo ;

Pluta, Andrzej ;

Wach, Malgorzata ;

Lysak, Daniel ;

Simkovic, Martin ;

Kriachok, Iryna ;

Illes, Arpad ;

de la Serna, Javier ;

Dolan, Sean ;

Campbell, Philip ;

Musuraca, Gerardo ;

Jacob, Abraham ;

Avery, Eric J. ;

Lee, Jae Hoon ;

Usenko, Ganna ;

Min Hui Wang ;

Yu, Ting ;

Jurczak, Wojciech .

HEMASPHERE, 2022, 6 (12) :E801

[9] Ibrutinib versus previous standard of care: an adjusted comparison in patients with relapsed/refractory chronic lymphocytic leukaemia [J].

Hansson, Lotta ;

Asklid, Anna ;

Diels, Joris ;

Eketorp-Sylvan, Sandra ;

Repits, Johanna ;

Soltoft, Frans ;

Jaeger, Ulrich ;

Osterborg, Anders .

ANNALS OF HEMATOLOGY, 2017, 96 (10) :1681-1691

[10]

Hillmen P., 2015, Blood

← 1 2 →